Cardeon raises $22 million to support COBRA trial
This article was originally published in Clinica
Private company Cardeon has closed a $22 million series D funding round. The company, which makes products aimed at minimizing the risk of the adverse effects of cardiac surgery, will use the funds to continue its clinical trial and to prepare for the European launch of its first product, the COBRA catheter. The product is an investigational device pending FDA approval for general clinical use.